1 Introduction 9
1.1 Definition 9
1.2 Scope of Study 9
1.3 Research Objective 9
1.4 Assumptions & Limitations 10
1.4.1 Assumptions 10
1.4.2 Limitations 10
1.5 Market Structure 11
2 Research Methodology 12
2.1 Research Process 12
2.2 Primary Research 13
2.3 Secondary Research 13
3 Market Dynamics 14
3.1 Introduction 14
3.2 Drivers 15
3.2.1 Rise in number of mitochondrial myopathy incidence rate and growing number of screening services. 15
3.2.2 Government funding and incentives for rare genetic diseases 15
3.3 Restraints 16
3.3.1 Poor treatment options and absence of curative treatment 16
3.3.2 Lack of awareness and diagnosis of the rare mitochondrial disorders 16
3.4 Opportunities 16
3.4.1 Faster market uptake and low marketing cost 16
3.4.2 Research and development 17
3.5 Challenges 17
3.5.1 Rare nature of the disease 17
3.5.2 Poor understanding of mitochondria and genetics 17
3.5.3 Cost of drug development and high investment risk 17
4 Market Factor Analysis 19
4.1 Porter's Five Forces Analysis 19
4.1.1 Threat from a New Entrant 19
4.1.2 Bargaining Power of Buyer 20
4.1.3 Bargaining Power of Supplier 21
4.1.4 Threat from substitute 21
4.1.5 Intensity of Competitive Rivalry 21
4.2 Pipeline Analysis 23
4.2.1 Introduction 23
4.2.2 KH176 23
4.2.3 Elamipretide 24
4.2.4 RTA 408 25
4.2.5 IXC 103 26
4.2.6 NV556 26
4.3 Mega Trends 27
4.3.1 Strategies for increasing mitochondrial biogenesis 27
4.3.2 Antioxidant approaches 27
4.3.3 Targeting mitochondrial dynamics and biogenesis 28
4.3.4 Mitochondrial membrane lipids as therapeutic targets 28
4.3.5 Nucleoside replacement and gene therapy 28
4.3.6 Enzyme replacement therapy 28
4.4 Investment Opportunity Analysis 29
4.4.1 Market size (current and future), growth rate, and profitability 29
4.4.2 Investment Risks 29
4.4.3 Market Outlook 29
4.4.4 Competitors 30
4.4.5 Projections 30
5 Global Mitochondrial Myopathy Diagnosis & Treatment Market, By Type 31
5.1 Introduction 31
5.2 Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS) 31
5.3 Progressive External Ophthalmoplegia (PEO) 31
5.4 Myoclonic Epilepsy with Ragged Red Fibres (MERRF) 32
5.5 Mitochondrial Neurogastrointestinal Encephalopathy Syndrome (MNGIE) 32
5.6 Kearns-Sayre Syndrome (KSS) 32
5.7 Mitochondrial DNA Depletion Syndrome (MDS) 32
5.8 Pearson Syndrome 33
5.9 Leigh Syndrome 33
5.10 Neuropathy, Ataxia, and Retinitis Pigmentosa (NARP) 33
6 Global Mitochondrial Myopathy Diagnosis & Treatment Market, By Diagnostic Test 36
6.1 Introduction 36
6.2 Genetic Tests 36
6.3 Muscle Biopsy 36
6.4 Biochemical Test 37
7 Global Mitochondrial Myopathy Diagnosis & Treatment Market, By Therapy 39
7.1 Introduction 39
7.2 Supportive Therapy 39
7.3 Targeted Therapy 40
8 Global Mitochondrial Myopathy Diagnosis & Treatment Market, By Region 42
8.1 Introduction 42
8.2 Americas 44
8.3 Europe 45
8.4 Asia-Pacific 47
8.5 Middle East & Africa 48
9 Company Profile 49
9.1 AbbVie Inc. 49
9.1.1 Company Overview 49
9.1.2 Product Overview 49
9.1.3 Financial Overview 49
9.2 Centogene AG 51
9.2.1 Company Overview 51
9.2.2 Product Overview 51
9.2.3 Financial Overview 51
9.2.4 Key Development 51
9.3 GeneDx 52
9.3.1 Company Overview 52
9.3.2 Product Overview 52
9.3.3 Financial Overview 52
9.3.4 Key Development 52
9.4 Ixchel Pharma 53
9.4.1 Company Overview 53
9.4.2 Product Overview 53
9.4.3 Financial Overview 53
9.5 Khondrion BV 54
9.5.1 Company Overview 54
9.5.2 Product Overview 54
9.5.3 Financial Overview 54
9.5.4 Key Development 54
9.6 Mitobridge 55
9.6.1 Company Overview 55
9.6.2 Product Overview 55
9.6.3 Financial Overview 55
9.7 NeuroVive Pharmaceutical AB 56
9.7.1 Company Overview 56
9.7.2 Product Overview 56
9.7.3 Financial Overview 56
9.7.4 Key Development 57
9.8 Reata Pharmaceuticals Inc. 58
9.8.1 Company Overview 58
9.8.2 Product Overview 58
9.8.3 Financial Overview 58
9.9 Stealth Biotherapeutics 60
9.9.1 Company Overview 60
9.9.2 Product Overview 60
9.9.3 Financial Overview 60
9.9.4 Key Developments 60